Development and current utility of infobases in Czech cancer care

Česká verzia

Authors: Ladislav Dušek ^1,2; Milan Bláha ^1,2; Jan Mužík ^1,2; Ondřej Májek ^1,2; Tomáš Pavlík ¹; Petr Klika ¹; Daniel Klimeš ¹; Denisa Malúšková ¹; Jakub Gregor ¹; Michal Burger ^1,2; Petr Brabec ¹
Authors place of work: Institut biostatistiky a analýz MU Brno, ředitel doc. RNDr. Ladislav Dušek, Ph. D. ¹; Ústav zdravotnických informací a statistiky Praha, ředitel doc. RNDr. Ladislav Dušek, Ph. D. ²
Published in the journal: Vnitř Lék 2014; 60(Suppl 2): 28-35
Category: 70th Birthday - prof. MUDr. Jiří Vorlíček, CSc.

Summary

Evaluation of the quality and effectiveness of health care is an integral part of modern health care. It can only be performed with sufficiently detailed data sources describing each segment of care. In case of significant heterogeneity and lack of standardization of hospital information systems it is necessary to fully exploit existing parametric data sources. The valid systems for Czech cancer care: the National Cancer Registry, clinical registries of Czech Society for Oncology of the Czech Medical Association of J.E. Purkyne, registries of screening programs and administrative data form healthcare payers. From these registries we can obtain a very complex and detailed view on prevention, diagnosis and cancer treatment in the Czech Republic. To achieve this goal, which means more integrated and comprehensive utilization of national registries, surveys and administrative data, it is necessary to fully utilize and apply the current legislative framework, in particular provision of the Act no. 372/2011 Sb.

Key words:
clinical registry – evaluation of health care – information system – legislation – malignant tumor – population

Zdroje

1. Český statistický úřad. Vývoj obyvatelstva ČR v mezinárodním srovnání v letech 1989 až 2000. Dostupné z WWW: <http://www.czso.cz/csu/2002edicniplan.nsf/p/1604–02>.

2. Esteve J, Benhamou E, Raymond L. Statistical Methods in Cancer Research. Volume IV – Descriptive Epidemiology. IARC Scientific Publications No. 128. Dostupné z WWW: <http://www.iarc.fr/en/publications/pdfs-online/stat/sp128/index.php.>.

3. Remontet L, Esteve J, Bouvier AM et al. Cancer incidence and mortality in France over the period 1978–2000. Rev Epidemiol Sante Publique 2003; 51(1 Pt 1): 3–30.

4. Kawamoto K, Houlihan CA, Balas EA et al. Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical to success. BMJ 2005; 330(7494): 765.

5. Dick RS, Steen RB. The Computer-Based Patient Record: An Essential Technology For Health Care. National Academy Press: Washington DC 1991. ISBN-13: 978–0309044950.

6. Dušek L, Abrahámová J, Indrák K et al. Registrace epidemiologických dat v onkologii a její význam pro hodnocení kvality léčebné péče. Klin Onkol 2004; 17(Suppl 1): S39-S44.

7. Murphy E, Dingwall R, Greatbatch D et al. Qualitative research methods in health technology assessment: a review of the literature. Health Technol Assess 1998; 2(16): iii-ix, 1–274.

8. Kristensen FB, Horder M, Poulsen P (eds). Health Technology Assessment Handbook. 2nd ed. Danish Institute for HTA: Copenhagen: 2001. ISBN 87–90951–86–7.

9. NCI. Common Toxicity Criteria Manual. Version 2.0. June 1. 1999. Dostupné z WWW: <http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcmanual_v4_10–4-99.pdf>.

10. European Organization for Research and Treatment of Cancer. A Practical Guide to EORTC Studies. EORTC Data Center: Brussels 1996.

11. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. Masarykova univerzita 2005. Dostupné z WWW: <http://www.svod.cz>.

12. Dušek L, Žaloudík J (eds). Hodnocení zdravotnických technologií v onkologii. Klin Onkol 2004; 17(suppl 1): S1-S104.

13. Berrino F, DeAngelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol 2007; 8(9): 773–783.

14. Capocaccia R, De Angelis R. Estimating the completeness of prevalence based on cancer registry data. Stat Med 1997; 16(4): 425–440.

15. Verdecchia A, De Angelis G, Capocaccia R. Estimation and projections of cancer prevalence from cancer registry data. Stat Med 2002; 21(22): 3511–3526.

16. Capocaccia D, Gatta G, Roazzi P et al. The EUROCARE-3 database: methodology of data collection, standardization, quality control and statistical analysis. Annals Oncol 2003; 14(Suppl 5): v14-v27.

17. Dušek L, Žaloudík J, Indrák K (eds). Informační zázemí pro využití onkologických populačních dat v ČR. Klin Onkol 2007; 20(Suppl 1): 52–196.

18. dos Santos Silva I. Cancer Epidemiology: Principles and Methods. International Agency for Research on Cancer: Lyon 1999. ISBN 92 832 0405 0.

19. Dušek L (ed). Czech Cancer Care in Numbers 2008–2009. Grada Publishing: Praha 2009. ISBN 978–80–247–3244–2.

20. Pavlík T, Májek O, Büchler T et al. Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000–2008. Cancer Epidemiol 2014; 38(1): 28–34.

21. Pavlík T, Májek O, Mužík J et al. Estimating the number of colorectal cancer patients treated with anti-tumour therapy in 2015: the analysis of the Czech National Cancer Registry. BMC Public Health 2012; 12: 117.

22. Zavoral M, Suchánek S, Májek O et al. Colorectal cancer screening: 20 years of development and recent progress. World J Gastroenterol 2014; 20(14): 3825–3834.

23. Suchánek S, Májek O, Vojtěchová G et al. Colorectal cancer prevention in the Czech Republic: time trends in performance indicators and current situation after 10 years of screening. Eur J Cancer Prev 2014; 23(1): 18–26.

24. Májek O, Daneš J, Skovajsová M et al. Breast cancer screening in the Czech Republic: time trends in performance indicators during the first seven years of the organised programme. BMC Public Health 2011; 11: 288.

25. West M, Ginsburg GS, Huang AT et al. Embracing the complexity of genomic data for personalized medicine. Genome Res 2006; 16(5): 559–566.

26. Collins CD, Purohit S, Podolsky RH et al. The application of genomic and proteomic technologies in predictive, preventive and personalized medicine. Vascul Pharmacol 2006; 45(5): 258–267.

27. Blaha M, Klika P, Janča D et al. Vývoj analytického nástroje pro podporu hodnocení onkologické péče (I-COP). MEFANET 2010. Masarykova univerzita: Brno 2010. ISBN 978–80–7392–141–5.

28. Blaha M, Janča D, Klika P et al. Project I-COP – architecture of software tool for decision support in oncology. Stud Health Technol Inform 2013; 186: 130–134.

29. Perry N, Broeders M, de Wolf C et al (eds). European guidelines for quality assurance in breast cancer screening and diagnosis. 4th ed. Office for Official Publications of the EC. Luxembourg 2006. ISBN 92–79–01258–4.

30. Arbyn M, Anttila A, Jordan J et al (eds). European guidelines for quality assurance in cervical cancer screening. 2nd ed. European Communities: Luxembourg 2008. ISBN 978–92–79–07698–5.

31. Anttila A, Ponti A, Ronco G et al. Interface of cancer registries with cancer screening programmes. Project Eurocourse 2010. Dostupné z WWW: <http://www.eurocourse.org>.

32. Segnan N, Patnick J, von Karsa L (eds). European guidelines for quality assurance in colorectal cancer screening and diagnosis. Office for Official Publications of the EC: Luxembourg 2010. ISBN 978–92–79–16435–4.

33. Májek O, Daneš J, Skovajsová M et al. Mamo.cz – Program mamografického screeningu v České republice [Internet]. Masarykova univerzita: Brno 2014. ISSN 1804–0861. Dostupné z WWW: <http://www.mamo.cz.>

34. Dušek L, Zavoral M, MájekO et al. Kolorektum.cz – Program kolorektálního screeningu v České republice [Internet].: Masarykova univerzita: Brno 2014. ISSN 1804–0888. Dostupné z WWW: <http://www.kolorektum.cz>.

35. Májek O, Dvořák V, Dušek L et al. Cervix.cz – Program cervikálního screeningu v České republice. Masarykova univerzita: Brno 2014. ISSN 1804–087X. Dostupné z WWW: